| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price |
|---|---|---|---|---|---|---|---|---|
| Galectin-3 | Human Galectin-3 Protein, His Tag | Human | E. coli | ![]() | SDS-PAGE | $340.00 200ug | ||
| Galectin-3 | Human Galectin-3 Protein, His Tag | Human | HEK293 | ![]() | SDS-PAGE | $300.00 100ug | ||
| Galectin-3 | Avitag GA3-H82E3 | Biotinylated Human Galectin-3 Protein, His,Avitag™ | Human | HEK293 | ![]() | SDS-PAGE | $360.00 25ug |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Olitigaltin | GB-0139; TD-139 | Phase 2 Clinical | Lund University Foundation, The University Of Edinburgh | Coronavirus Disease 2019 (COVID-19); Idiopathic Pulmonary Fibrosis | Details |
| Galactomannan C | GM-CT-01 | Phase 2 Clinical | Galectin Therapeutics Inc | Bile Duct Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Coronavirus Disease 2019 (COVID-19); Gallbladder Neoplasms; Head and Neck Neoplasms; Lung Neoplasms; Melanoma; Prostatic Neoplasms | Details |
| Selvigaltin | GB-1211; GB1211 | Phase 2 Clinical | Galecto Inc | Carcinoma, Non-Small-Cell Lung; Hepatic Insufficiency; Melanoma; Metabolic Dysfunction-Associated Steatotic Liver Disease; Multiple Myeloma; Squamous Cell Carcinoma of Head and Neck | Details |
| ProLectin-M | Phase 2 Clinical | BioXyTran Inc | Coronavirus Disease 2019 (COVID-19); Cytokine Release Syndrome; Influenza, Human | Details | |
| Gal-400 | Gal-400 | Phase 1 Clinical | Galecto Inc | Liver Cirrhosis; Metabolic Dysfunction-Associated Steatotic Liver Disease | Details |
| Belapectin | GR-MD-02 | Phase 1 Clinical | Galectin Therapeutics Inc | Carcinoma, Non-Small-Cell Lung; Esophageal and Gastric Varices; Hepatic Insufficiency; Hypertension, Portal; Liver Cirrhosis; Melanoma; Metabolic Dysfunction-Associated Steatotic Liver Disease; Psoriasis; Squamous Cell Carcinoma of Head and Neck | Details |
| SIF-001 | SIF001 | Phase 1 Clinical | Suninflam Inc | Epilepsy; Neuroinflammatory Diseases | Details |
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Ocriplasmin | A-01016; THR-409 | Approved | Thrombogenics | Jetrea, Jejetrea | United States | Vitreomacular Adhesion | Thrombogenics Inc | 2012-10-17 | Arterial Occlusive Diseases; Diabetic macular oedema; Diabetic Retinopathy; Disease Progression; Eye Diseases; Macular Degeneration; Retinal Diseases; Retinal Vein Occlusion; Stroke; Uveitis; Venous Thrombosis; Vitreomacular Adhesion; Vitreous Detachment | Details |